GI Innovation Inc
KOSDAQ:358570
GI Innovation Inc
Research & Development
GI Innovation Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Research & Development
-₩34.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩218.9B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Research & Development
-₩71.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩95.6B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Research & Development?
Research & Development
-34.3B
KRW
Based on the financial report for Dec 31, 2024, GI Innovation Inc's Research & Development amounts to -34.3B KRW.
What is GI Innovation Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-14%
Over the last year, the Research & Development growth was 15%. The average annual Research & Development growth rates for GI Innovation Inc have been -14% over the past three years .
